Journals / Ege Tıp Dergisi / 2019 / Cilt: 58 - Sayı: 0

The role of fibromyalgia in rheumatic diseases

Romatolojik hastalıklarda fibromiyaljinin payı

Pages
38–42
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, the prevalence and pathophysiology of concomitant FMS in different rheumatic diseases and its impact on underlying inflammatory condition will be highlighted.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Fibromyalgia syndrome (FMS) is a clinical disorder characterized by chronic diffuse musculoskeletal pain, numerous discrete tender points and multiple somatic and cognitive symptoms, without any specific laboratory and imaging findings.
📊
Key Findings & Data:Comorbid FMS may lead to increased disease activity scores, leading to an inaccurate impression of disease severity.
💡
Conclusion & Impact:In this review, the prevalence and pathophysiology of concomitant FMS in different rheumatic diseases and its impact on underlying inflammatory condition will be highlighted.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Fibromyalgia syndrome (FMS) is a clinical disorder characterized by chronic diffuse musculoskeletal pain, numerous discrete tender points and multiple somatic and cognitive symptoms, without any specific laboratory and imaging findings. Prevalence of FMS is higher in chronic inflammatory arthritis, compared to the general population. Comorbid FMS may lead to increased disease activity scores, leading to an inaccurate impression of disease severity. Thus, it is important to recognize comorbid FMS for the optimal management of rheumatic diseases. Disease activity indices should be cautiously interpreted, and objective clinical measurements should be considered in patients with comorbid FMS. In this review, the prevalence and pathophysiology of concomitant FMS in different rheumatic diseases and its impact on underlying inflammatory condition will be highlighted.

Özet

Fibromiyalji sendromu (FMS), kronik yaygın kas-iskelet ağrısı, yaygın hassas noktalar, multipl somatik ve bilişsel problemlerle karakterize, spesifik laboratuvar ve görüntüleme bulgusu olmayan klinik bir sendromdur. Kronik romatolojik hastalıklarda FMS prevalansının genel popülasyona göre daha yüksek olduğu gösterilmiştir. Komorbid FMS hastalık aktivite skorlarının yükselmesine, dolayısıyla romatolojik hastalığın şiddetinin yanlış değerlendirilmesine ve gereksiz tedavilerin verilmesine neden olabilir. Bu nedenle eşlik eden FMS’nun tanınması, romatolojik hastalığın optimal tedavisi için önem taşır. Komorbid FMS olan olgularda hastalık aktivite göstergeleri dikkatle yorumlanmalı, objektif klinik ölçütler göz önünde bulundurulmalıdır. Bu derlemede, değişik romatolojik hastalıklarda komorbid FMS prevalansı, patofizyolojisi ve altta yatan inflamatuvar hastalık üzerindeki etkileri gözden geçirilecektir.

🔖

Cite This Article

ON, A. (2019). The role of fibromyalgia in rheumatic diseases. Ege Tıp Dergisi, Cilt: 58 - Sayı: 0, 38–42. https://ajindex.com/articles/161343

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Wolfe F, Hugh A. Smythe, et al. The American Collage of Rheumatology 1990 Criteria for The Classification of Fibromyalgia. Arthritis Rheum 1990;33(1):24-32
  2. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalance and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995;38(1):19-28
  3. Inanici F, Yunus MB. History of fibromyalgia: past to present. Curr Pain Headache Rep 2004;8(5):369-78
  4. William S, Wılke MD. New developments in the diagnosis of fibromyalgia syndrome: Say goodbye to tender points? Cleve Clin J Med 2009;76:345-52
  5. Wolfe F, Clauw DJ, Fitzcharles MA, et al. The American Collage of Rheumatology Preliminary Diagnostic Criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res 2010;62 (5):600-10
  6. Wolfe F, Clauw DJ, Fitzcharles MA et al. Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR preliminary diagnostic criteria for fibromyalgia. J Rheumatol 2011;38(6):1113-22
  7. White KP, Speechley M, Harth M, Ostbye T. The London Fibromyalgia Epidemiology Study: the prevalance of fibromyalgia syndrome in London, Ontorio. J Rheumatol 1999;26:1570-6
  8. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalance and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995;38(1):19-28
  9. Topbaş M, Çakırbay H, Güleç H, et al. The prevalence of fibromyalgia in women aged 20-64 in Turkey. Scand J Rheumatol 2005;34 (2):140-4
  10. Sarzi-Puttini P, Atzeni F, Mease PJ. Choronic widespread pain: from peripheral to central evolution. Best Pract Res Clin Rheumatol 2011;25:133-9
  11. Schmidt-Wilcke T, Clauw DJ. Fibromyalgia: from pathophysiology to therapy. Nat Rev Rheumatol 2011;7:518-27
  12. Staud R, Cannon RC, Mauderli AP, et al. Temporal summation of pain from mechanical stimulation of muscle tissue in normal controls and subjects with fibromyalgia syndrome. Pain 2003;102 (1-2): 87-95
  13. Gracely RH, Petzke F, Wolf JM, et al. Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum 2002;46: 1333-43
  14. Cook DB, Lange G, Ciccone DS, et al. Functional imaging of pain in patients with primary fibromyalgia. J Rheumatol 2004;31:364-78
  15. Yunus MB. Central sensitivity syndromes: A new paradigm and group nosology for fibromyalgia and overlapping conditions and the related issue of disease versus illness. Semin Arthritis Rheum 2008;37(6):339-52
  16. On AY: